Daniel L Labovitz1, Laura Shafner2, Morayma Reyes Gil1, Deepti Virmani1, Adam Hanina1. 1. From the Montefiore Medical Center, Bronx, New York (D.L.L., M.R.G., D.V.); and AiCure, New York, NY (L.S., A.H.). 2. From the Montefiore Medical Center, Bronx, New York (D.L.L., M.R.G., D.V.); and AiCure, New York, NY (L.S., A.H.). laura.shafner@aicure.com.
Abstract
BACKGROUND AND PURPOSE: This study evaluated the use of an artificial intelligence platform on mobile devices in measuring and increasing medication adherence in stroke patients on anticoagulation therapy. The introduction of direct oral anticoagulants, while reducing the need for monitoring, have also placed pressure on patients to self-manage. Suboptimal adherence goes undetected as routine laboratory tests are not reliable indicators of adherence, placing patients at increased risk of stroke and bleeding. METHODS: A randomized, parallel-group, 12-week study was conducted in adults (n=28) with recently diagnosed ischemic stroke receiving any anticoagulation. Patients were randomized to daily monitoring by the artificial intelligence platform (intervention) or to no daily monitoring (control). The artificial intelligence application visually identified the patient, the medication, and the confirmed ingestion. Adherence was measured by pill counts and plasma sampling in both groups. RESULTS:For all patients (n=28), mean (SD) age was 57 years (13.2 years) and 53.6% were women. Mean (SD) cumulative adherence based on the artificial intelligence platform was 90.5% (7.5%). Plasma drug concentration levels indicated that adherence was 100% (15 of 15) and 50% (6 of 12) in the intervention and control groups, respectively. CONCLUSIONS: Patients, some with little experience using a smartphone, successfully used the technology and demonstrated a 50% improvement in adherence based on plasma drug concentration levels. For patients receiving direct oral anticoagulants, absolute improvement increased to 67%. Real-time monitoring has the potential to increase adherence and change behavior, particularly in patients on direct oral anticoagulant therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02599259.
RCT Entities:
BACKGROUND AND PURPOSE: This study evaluated the use of an artificial intelligence platform on mobile devices in measuring and increasing medication adherence in strokepatients on anticoagulation therapy. The introduction of direct oral anticoagulants, while reducing the need for monitoring, have also placed pressure on patients to self-manage. Suboptimal adherence goes undetected as routine laboratory tests are not reliable indicators of adherence, placing patients at increased risk of stroke and bleeding. METHODS: A randomized, parallel-group, 12-week study was conducted in adults (n=28) with recently diagnosed ischemic stroke receiving any anticoagulation. Patients were randomized to daily monitoring by the artificial intelligence platform (intervention) or to no daily monitoring (control). The artificial intelligence application visually identified the patient, the medication, and the confirmed ingestion. Adherence was measured by pill counts and plasma sampling in both groups. RESULTS: For all patients (n=28), mean (SD) age was 57 years (13.2 years) and 53.6% were women. Mean (SD) cumulative adherence based on the artificial intelligence platform was 90.5% (7.5%). Plasma drug concentration levels indicated that adherence was 100% (15 of 15) and 50% (6 of 12) in the intervention and control groups, respectively. CONCLUSIONS:Patients, some with little experience using a smartphone, successfully used the technology and demonstrated a 50% improvement in adherence based on plasma drug concentration levels. For patients receiving direct oral anticoagulants, absolute improvement increased to 67%. Real-time monitoring has the potential to increase adherence and change behavior, particularly in patients on direct oral anticoagulant therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02599259.
Authors: Terrence F Blaschke; Lars Osterberg; Bernard Vrijens; John Urquhart Journal: Annu Rev Pharmacol Toxicol Date: 2011-09-19 Impact factor: 13.820
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Xiaoxi Yao; Neena S Abraham; G Caleb Alexander; William Crown; Victor M Montori; Lindsey R Sangaralingham; Bernard J Gersh; Nilay D Shah; Peter A Noseworthy Journal: J Am Heart Assoc Date: 2016-02-23 Impact factor: 5.501
Authors: Delbert G Robinson; Nina R Schooler; Robert A Rosenheck; Haiqun Lin; Kyaw J Sint; Patricia Marcy; John M Kane Journal: Psychiatr Serv Date: 2019-05-14 Impact factor: 3.084
Authors: Monica Gandhi; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Jared M Baeten; Oraphan Siriprakaisil; Virat Klinbuayaem; Warren C Rodrigues; Guohong Wang; Michael Vincent; Tim R Cressey; Paul K Drain Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Albert Y Liu; Nicole D Laborde; Kenneth Coleman; Eric Vittinghoff; Rafael Gonzalez; Gretchen Wilde; Annie L Thorne; Ed Ikeguchi; Laura Shafner; Lauren Sunshine; Ariane van der Straten; Aaron J Siegler; Susan Buchbinder Journal: AIDS Behav Date: 2020-10-12
Authors: Mohammad El-Ghanem; Francisco E Gomez; Prateeka Koul; Rolla Nuoman; Justin G Santarelli; Krishna Amuluru; Chirag D Gandhi; Eric R Cohen; Philip Meyers; Fawaz Al-Mufti Journal: Interv Neurol Date: 2018-12-13